Safety of cell immunotherapy for refractory malignant tumor using natural killer cell-like effector cells (CA-MED-NK001) selectively amplified from autologous mononuclear cells in peripheral blood - Safety of cell immunotherapy for refractory malignant tumor using CA-MED-NK001 cells

Center for Advanced Medical Innovation, Kyushu University0 个研究点目标入组 10 人开始时间: 2014年11月21日最近更新: 2023年10月17日

适应症

试验速览

This trial has been terminated due to the difficulties of the recruitment of condition-matched subjects after the entry of four patients.

•Patients to be excluded would satisfy any of the following conditions: (1) pulmonary fibrosis and/or interstitial pneumonia (2) patients who have a history of severe drug allergy (3) serum positive for HBs antigen, HCV, HTLV-1 and/or HIV antibody (4) active autoimmune disease (5) patients who are taking steroids and/or immunosuprresive agents (6) double or more cancers (7) uncontrolable infectious disease (8) Patients to be or wishing for pregnancy, or breast-feeding (9) T cell- or NK cell-originated leukemia and/or lymphoma (10) heavy cardiological disease (11) Patientss who are regarded as inadequate for study enrollment by the investigator

发起方

Center for Advanced Medical Innovation, Kyushu University